<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02907554</url>
  </required_header>
  <id_info>
    <org_study_id>CHU-0276</org_study_id>
    <secondary_id>2014-003544-12</secondary_id>
    <nct_id>NCT02907554</nct_id>
  </id_info>
  <brief_title>Cyclosporine A Pretreatment and Kidney Graft Function</brief_title>
  <acronym>Cys-A-Rein</acronym>
  <official_title>Effects of Cyclosporine A Pretreatment of Deceased Donor on Kidney Graft Function: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Estaing</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Groupe Hospitalier Pitie-Salpetriere</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôtel Dieu (Nantes)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital de la Timone</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Organ donors included in the study are randomized to a control group or an intervention group
      receiving 2.5 mg/kg of cyclosporine A before organ procurement. Harvested kidneys from these
      patients are transplanted to chronic kidney insufficiency patients. According to the
      pretreatment of the transplant, delayed graft function during the first week was evaluated as
      well as kidney function at different timepoints and mortality during the first year after
      transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Organ donors included in the study are randomized to a control group receiving a placebo or
      an intervention group receiving 2.5 mg/kg of cyclosporine A before organ procurement. In the
      operating theater organs are harvested. Thereafter, harvested kidneys from these patients are
      transplanted to chronic kidney insufficiency patients. The management of transplanted
      patients is performed as usual. According to the pretreatment of the transplant, delayed
      graft function during the first week (need of at least one dialysis session) was evaluated as
      well as kidney function at different timepoints (slow graft function, estimated creatinine
      clearance on day 3 and 7, acute and chronic graft rejection), length of hospital stay and
      mortality during the first year after transplantation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 19, 2017</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of delayed graft function defined by a need of at least one hemodialysis session</measure>
    <time_frame>within the 7 days following renal transplantation.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of slow graft function defined by a urine output &lt; 1000 ml</measure>
    <time_frame>at on 1 day after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of slow graft function defined by a decrease in plasma creatinine concentration of less than 30% or 70%</measure>
    <time_frame>at day 3 and 7 after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative evolution of estimated creatinine clearance</measure>
    <time_frame>at day 3 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of acute and chronic graft rejection</measure>
    <time_frame>during the first year after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of primary graft dysfunction</measure>
    <time_frame>during the first year after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospital length of stay</measure>
    <time_frame>at day 1</time_frame>
    <description>after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>during the first year after transplantation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">648</enrollment>
  <condition>Brain Death</condition>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>control group receives a placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the intervention group receives 2.5 mg/kg of cyclosporine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine A</intervention_name>
    <description>the intervention group receives 2.5 mg/kg of cyclosporine</description>
    <arm_group_label>intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>control group receives a placebo</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For organ donors:

          -  Male and females aged 18 to 70 years

          -  Brain death

        Inclusion criteria for organ recipients:

          -  Male and females aged 18 to 70 years

          -  Indication of kidney transplantation

          -  Informed consent

        Exclusion Criteria:

        For organ donors:

          -  Contra-indication for multiorgan procurement (infections, cancer, etc)

          -  Preexistent chronic renal failure.

          -  Refusal for organ procurement by the donor (confirmed by the French national register
             or reported by the next-of-kin).

        Exclusion criteria for organ recipients:

          -  Need for a double kidney transplantation.

          -  Need for a multiorgan transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carole ICHAI</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Nice</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick LACARIN</last_name>
    <phone>04 73 75 11 95</phone>
    <email>placarin@chu-clermontefrrand.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick LACARIN</last_name>
      <phone>04 73 75 11 95</phone>
      <email>placarin@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2016</study_first_submitted>
  <study_first_submitted_qc>September 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2016</study_first_posted>
  <last_update_submitted>February 26, 2018</last_update_submitted>
  <last_update_submitted_qc>February 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Preconditioning</keyword>
  <keyword>Tissue and organ procurement</keyword>
  <keyword>Cyclosporine A</keyword>
  <keyword>Kidney transplantation</keyword>
  <keyword>Delayed graft function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Death</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

